* = user login access

New Nuclear Radiation Treatment

Houston Chronicle via myplainview.com - Tuesday July 05, 2005
Artlce Link

. . .A California pharmaceutical firm, Hollis-Eden, is working with the Armed Forces Radiobiology Research Institute to develop a steroid hormone that would treat Acute Radiation Syndrome and drastically lower fatality levels in the event of a nuclear catastrophe. Exposure to severe levels of radiation damages the ability of human bone marrow to produce white blood cells and leads to death by opportunistic infection. According to a Hollis-Eden spokesman, the drug Neumune bolsters the bodyﾴs immune system and allows a treated victim to survive lethal doses of radiation.

In tests on rhesus monkeys, the drug provided immunity for 90 percent of the animals exposed to high levels of radiation. If Neumune receives Food and Drug Administration approval, it will be tested on human volunteers to establish that it is nontoxic. After that, company executives are looking to sell millions of doses to the federal government under the Project BioShield law, which allocated $5.6 billion to purchase products to fight bioterrorism 75 million doses of anthrax vaccine already have been ordered.. . .

This website is intended for informational purposes only and is not in any way affiliated with the military.

Website designed and maintained by HealthSentinel.com